Ara
Toplam kayıt 7, listelenen: 1-7
Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy
(Sage Publications Ltd, 2018)
Background: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and ...
Clinicopathological factors in non-small cell lung cancer patients with bone metastases
(Elsevier Science, 2015)
…
Is change in hemoglobin level a predictive biomarker of tyrosine kinase efficacy in metastatic renal cell carcinoma? A Turkish oncology group study
(Taylor & Francis Inc., 2017)
Background: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly ...
Treatment preferences in stage IA and IB testicular seminoma: Multicenter study of anatolian society of medical oncology
(Springer, 2015)
Approximately 75 % of patients with testicular seminoma present with stage I disease, and the probability of long-term survival approaches 100 %. However, the standard adjuvant treatment for stage I seminoma patients remains ...
Prognostic factors related with survival in patients with pancreatic adenocarcinoma
(Baishideng Publishing Group, 2014)
The prognosis in patients with pancreatic cancer is poor and this cancer is the fourth leading cause of cancer-related death worldwide. Although surgical resection is the only curative treatment of choice for pancreatic ...
Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer who underwent curative gastrectomy
(Springer, 2015)
Proximal gastric cancer has a high propensity of early recurrence after curative resection due to high incidence of lymph node involvement. In the present study, we aimed to investigate the pattern and time of recurrence ...
Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer
(Springer, 2016)
Bevacizumab is a monoclonal antibody which is a vascular endothelial growth factor inhibitor. It obscures vascularization of tumor tissue and damages intratumoral microcirculation. The damaged intratumoral microcirculation ...